ESMO26: Sac-TMT’s OptiTROP-Lung04 survival gain holds, putting the onus on MSD

In the Phase III OptiTROP-Lung04 trial, sac-TMT extended median OS to 25.9 months in EGFR-mutated NSCLC. In the Phase III OptiTROP-Lung04 trial, sac-TMT extended median OS to 25.9 months in EGFR-mutated NSCLC. After a median follow-up of 32.3 months, Kelun-Biotech’s sac-TMT extended median OS to 25.9 months vs. 17.4 months with pemetrexed plus platinum chemotherapy in EGFR-mutated NSCLC. Outside Greater China, MSD holds the rights to the drug. Credit: NMK-Studio / Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free…

Source: Clinical Trials Arena